🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to researchers.

A Global Challenge

Gonorrhoea infections are on the rise worldwide, with estimates suggesting in excess of 82 million new cases each year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Health officials are increasingly worried about the increase in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the US FDA in recent days for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This authorization signifies a major breakthrough in the treatment of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Outcomes and Worldwide Availability

As per results released by a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This establishes an equal footing with the current standard treatment, which involves two antibiotics. The research included over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to make available and distribute the drug in numerous developing nations.

Clinicians treating patients have shared hope. Access to a single-dose, oral treatment like this is hailed as a "critical tool" for managing the epidemic. This is viewed as vital to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea worldwide.